A prospective peer-reviewed study published this month showed a higher number of heart inflammation or myocarditis and other cardiac side effects after the second dose of the Pfizer BNT162b2 COVID jab compared to previous studies.[1]
The C.D.C. maintains that myocarditis is a rare complication of COVID shots. Their data is based on the VAERS, a passive reporting system. Two Israeli studies presented below are retrospective.
Retrospective studies answer “what happened” and dig up the information. In contrast, the prospective studies, which is what this Thai research did, try to find out “what will happen.”
The Thai followed male and female high school students from the Royal Thai Army School and Wachiratham Satit School in Thailand who already had their first shot of the Pfizer COVID “vaccine.”
Laboratory tests were done on everybody. Those included cardiac biomarkers (troponin-T, creatine kinase-myocardial band (CK-MB)), E.C.G., and echocardiography were done at three to four clinical visits after receiving the second dose of the Pfizer BNT162b2 mRNA COVID-19 vaccine.
- Baseline
- Day 3
- Day 7
- Day 14 is optional for subjects with cardiac manifestation
Testing all subjects, regardless of whether they have a complaint, is significant because testing can detect myocarditis in those who don’t have cardiac complaints.
Patients’ medical complaints are subjective and differ from one another. For example, some people may not interpret the discomfort in their chest as chest pain and answer no. Others will have shortness of breath due to asthma before the vaccination and will not complain about it after their COVID shot.
If the study only looked at those who had medical complaints, those who did not talk about their problems would not get tested. This is what commonly happens.
The study protocol says that if the teenagers develop side effects from the vaccine, they can call the principal investigator and be transferred by phone to the medical team at the Hospital for Tropical Diseases for assessment.
If the participant develops abnormal E.C.G., echocardiographic findings, or increased cardiac enzymes, they are scheduled for follow-up and day 14 lab assessments.
Cardiovascular effects were found in 29.24% of patients, ranging from rapid heart rate, palpitations, and myopericarditis.
Higher numbers of COVID vaccine-related myocarditis
Four of 301 Thai teenagers had myocarditis, two had pericarditis, and one had myopericarditis after their second Pfizer shot.
If we include myopericarditis, five out of 301 had myocarditis. That is 1,660 myocarditis cases per 100,000!
[100,000/301=332. 332×5=1,660]
That’s a huge number! Consider that myocarditis in the general population is about 10-20 per 100,000 individuals per year without vaccination.[5]
In contrast, other studies show lower numbers of myocarditis after the Pfizer shots.
In two retrospective studies from Israel, the incidence of myocarditis after the second-dose mRNA COVID shot among those aged 16-29 is 2.13 cases per 100,000 persons.[2]
Another by Mevorach et al. [3] showed: (Emphases added)
The overall risk difference between the first and second doses (Pfizer) was 1.76 per 100,000 persons, with the largest difference among male recipients between the ages of 16 and 19 years at 13.73 per 100,000 persons.
The U.S. military reported only 23 cases out of 2.8 million doses of the mRNA COVID-19 vaccine.[4]
Other Significant findings
Two were hospitalized, and one patient was admitted to the intensive care unit to observe the arrhythmia. Arrythmias need close monitoring because they can suddenly become unstable and result in death. Both were discharged after 4.5 days.
No participants died or required mechanical ventilation or blood pressure-raising medicines.
Three patients diagnosed with myopericarditis and pericarditis were treated with nonsteroidal anti-inflammatory drugs (NSAIDs) (Ibuprofen is an example) for two weeks with no residual symptoms and complete follow-up.
29.4% out of 301 patients had cardiovascular symptoms:
-
- Rapid heart rate (tachycardia) (7.64%)
- Shortness of breath (6.64%)
- Palpitation (4.32%)
- Chest pain (4.32%)
- Hypertension (3.99%)
Other symptoms like fever (16.6%) and headache (11.6%) were observed. Note that some subjects may have more than one symptom, which is why the total is not 29.4%.
Seven participants (2.33%) exhibited at least one elevated cardiac biomarker indicative of heart muscle damage or abnormal laboratory values. Three of them had chest pain and biomarker elevation 24-48 hours after getting the shots.
Curiously, four patients had no symptoms but had elevated biomarkers (cTnT). This shows the advantage of a prospective study. If these four patients were not included, their abnormal biomarkers would never have been documented.
Abnormal E.C.G.
Abnormal E.C.G. finding was noted in 17.94% of the patients (54/301). The abnormal E.C.G. findings were: sinus rhythm with sinus arrhythmia (7.31%), sinus tachycardia or fast heart rate ( 6.64%), and sinus bradycardia or slow heart rate (1.33%).
Two patients had abnormal rhythms, one had a junctional escape rhythm, and another one had an ectopic atrial rhythm. Both are not alarming in healthy teenagers.
Two (0.66%) developed Premature ventricular contractions (P.V.C.), and three (1%) had premature atrial contractions (P.A.C.). P.V.C. and P.A.C.s are not dangerous.
One case (0.33%) had diffused S.T. elevation with P.R. depression consistent with inflammation of the sac surrounding the heart or pericarditis.
This study is relevant to Asians, particularly South East Asians, because the Pfizer clinical trials included only 8.2% Asians. Page 23 of BNT162b2 Vaccine Candidate Against COVID-19
Can COVID-19 cause myocarditis?
COVID shot proponents always say that it is good to have mRNA shots to protect against COVID-19-induced myocarditis.
However, those studies were based on COVID-19 from the pandemic’s beginning when the variants (D614G, Alpha, and Delta) were more virulent, and effective outpatient medicines for COVID-19 were not yet used.
When I searched for omicron+myocarditis+ncbi as of today, I found none. Plus, there are ways to prevent COVID now. The I-PREVENT COVID Protection Protocol and early outpatient treatment are available. The FLCCC I-CARE Early COVID Treatment Protocol.
Not all post-vaccine myocarditis is mild.
Many health websites, including the C.D.C., say it’s OK to assume the risk of myocarditis after the mRNA shots because the myocarditis cases are generally mild.
Myocarditis may be mild, but if it affects the heart in a deadly spot (sinoatrial node and atrioventricular node) where electrical conduction happens, a person can have a complete heart block. That’s what happened in two cases in other articles.
- Complete Heart Block after the Pfizer COVID shot
- Autopsy of a soldier who died of myocarditis after Pfizer COVID vaccination
Myocarditis can be fulminant and has ended the career of a Japanese athlete – A professional athlete who died of fulminant myocarditis after the Moderna jab.
The current SARS-CoV-2 dominant variants, BA.4 and BA.5, are highly transmissible but mild. That is consistent with the evolution of a pandemic. Should I be afraid of the omicron variant?
The risks outweigh the benefits of the COVID-19 shots.
Truth heals. Lies kill. Don’t Get Sick!
Knowledge about Covid-19 is rapidly evolving. Stay current by subscribing. Feel free to share and like. Please consider donating to show your support if you find value in this website.
Related:
- Myocarditis by age, sex, and COVID shot
- Anti-Idiotype Antibodies against the Spike Proteins may Explain Myocarditis
- Dr. Steven Gundry: mRNA Vaccination Increases the Risk of Acute Coronary Syndrome
- Kounis syndrome can explain vaccine-related heart attacks
- Myocarditis after mRNA Vaccination in the Military
- You Have to Know Vaccine-Related Kounis Syndrome
- Myocarditis and the COVID vaccine
- This Study shows Ten Fold risk of Developing Blood Clots after the COVID Vaccines.
- Platelet Changes Cause Blood Clots in COVID-19
- The High Risk of Deadly Brain Clots in the J & J COVID Vaccine
References:
- Mansanguan, S.; Charunwatthana, P.; Piyaphanee, W.; Dechkhajorn, W.; Poolcharoen, A.; Mansanguan, C. Cardiovascular Manifestation of the BNT162b2 mRNA COVID-19 Vaccine in Adolescents. Trop. Med. Infect. Dis. 2022, 7, 196.
- Witberg G, Barda N, Hoss S, Richter I, Wiessman M, Aviv Y, Grinberg T, Auster O, Dagan N, Balicer RD, Kornowski R. Myocarditis after Covid-19 Vaccination in a Large Health Care Organization. N Engl J Med. 2021;385(23):2132-39
- Mevorach D, Anis E, Cedar N, Bromberg M, Haas EJ, Nadir E, et al. Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel. N Engl J Med. 2021; 385(23): 2140-49.
- Montgomery J, Ryan M, Engler R, Hoffman D, McClenathan B, Collins L, Loran D, Hrncir D, Herring K, Platzer M, Adams N, Sanou A, Cooper LT Jr. Myocarditis Following Immunization With mRNA COVID-19 Vaccines in Members of the U.S. Military. JAMA Cardiol. 2021 Oct 1;6(10):1202-1206. doi: 10.1001/jamacardio.2021.2833. PMID: 34185045; PMCID: PMC8243257.
- Olejniczak M, Schwartz M, Webber E, Shaffer A, Perry TE. Viral Myocarditis-Incidence, Diagnosis, and Management. J Cardiothorac Vasc Anesth. 2020 Jun;34(6):1591-1601. doi: 10.1053/j.jvca.2019.12.052. Epub 2020 Jan 7. PMID: 32127272.
© 2018 – 2022 Asclepiades Medicine, L.L.C. All Rights Reserved
DrJesseSantiano.com does not provide medical advice, diagnosis, or treatment